Document Detail


Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.
MedLine Citation:
PMID:  23316969     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Gastrointestinal (GI) malignancies account for nearly one-fourth of all cancer-related deaths in the United States and approximately 30% of all cancer-related deaths worldwide. Use of combination cytotoxic therapy offers a modest improvement in survival, but the prognosis and long-term survival of most patients with GI cancer remains poor. In certain GI malignancies, therapies that target members of the HER family of receptors have positively impacted patient care.
AREAS COVERED: In this review, we discuss the significance of the HER family of receptors in esophagogastric, hepatobiliary, pancreatic, and colorectal cancers and explain the rationale supporting the use of monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs) to inhibit HER activation and downstream events that contribute to tumor proliferation, migration, and survival.
EXPERT OPINION: Despite recent advances, the treatment of GI cancers remains challenging. Therapies targeting the HER family of receptors have been extensively studied in these malignancies with inconsistent results. The rationale behind varied tumor responses with these agents remains uncertain. We believe that additional studies are needed to identify biomarkers that could help identify a population of patients who would be more responsive to a given therapy.
Authors:
Monica Dandona Desai; Bikramajit Singh Saroya; Albert Craig Lockhart
Related Documents :
24491129 - Gender roles and acculturation: relationships with cancer screening among vietnamese am...
24568479 - Single center experience on causes of cancer patients visiting the emergency department...
22283969 - Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminishe...
24698529 - Using client reminders to increase colorectal cancer screening in montana, 2012.
3293619 - Development of new immunologic approaches to cancer therapy.
22998509 - Novel aldose reductase inhibitors: a patent survey (2006--present).
23426449 - Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer.
22935909 - Development of artemisinin compounds for cancer treatment.
22357149 - Patient-related barriers to cancer pain management in jordan.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-15
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  22     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-30     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  341-56     Citation Subset:  IM    
Affiliation:
Washington University in St. Louis, Medicine, 660 S. Euclid Ave, Box 8056, St. Louis, MO 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Movement / drug effects
Cell Proliferation / drug effects
Cell Survival / drug effects
Gastrointestinal Neoplasms / drug therapy*,  enzymology,  pathology
Humans
Protein Kinase Inhibitors / therapeutic use*
Receptor, Epidermal Growth Factor / metabolism*
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; EC 2.7.10.1/Receptor, Epidermal Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ground State Transcriptional Requirements for Skin-Derived Precursors.
Next Document:  Arteriovenous fistula as a complication of transradial coronary angiography: a case report.